CO5611125A2 - Derivados de azetidina como antagonistas del receptor ccr-3 - Google Patents
Derivados de azetidina como antagonistas del receptor ccr-3Info
- Publication number
- CO5611125A2 CO5611125A2 CO04091228A CO04091228A CO5611125A2 CO 5611125 A2 CO5611125 A2 CO 5611125A2 CO 04091228 A CO04091228 A CO 04091228A CO 04091228 A CO04091228 A CO 04091228A CO 5611125 A2 CO5611125 A2 CO 5611125A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- denote
- optionally substituted
- phenyl
- heterocyclic group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Virology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
1.- Un compuesto según la Fórmula Ien forma de sal o libre, dondeAr es un fenilo opcionalmente substituido por uno o más substitutos seleccionados a partir de halógeno, C1-C8-alquilo, ciano o nitro;R1 es hidrógeno, o C1-C8-alquilo, opcionalmente substituido por hidroxi, C1-C8-alquilo, aciloxi, halógeno, carboxi, C1-C8-alcoxicarbonilo, -N(R4)R5, -CON(R6)R7 o por un grupo orgánico cíclico monovalente que tiene de 3 a 15 átomos en el sistema de anillo;R2 es hidrógeno, C1-C8-alquilo, o C3-C10-cicloalquilo, y R3 es C1-C8-alquilo substituido por fenilo, fenoxi, aciloxi o naftilo, o R3 es C3-C10-cicloalquilo que tiene opcionalmente un grupo benzo fusionado al mismo, un grupo heterocíclico que tiene 5 a 11 átomos de anillo de los cuales 1 a 4 son heteroátomos, fenilo o naftilo, substituyéndose opcionalmente dichos grupos fenilo, fenoxi o naftilo por uno o más substitutos seleccionados a partir de halógeno, ciano, hidroxi, acilo, nitro, -SO2NH2, C1-C8-alquilo opcionalmente substituido por C1-C8-alcoxi, C1-C8-haloalquilo, C1-C8-alcoxi, C1-C8-haloalcoxi, C1-C8-alquiltio, -SO2C1-C8-alquilo, C1-C8-alcoxicarbonilo, C1-C8-acilamino opcionalmente substituidos en el átomo de nitrógeno por C1-C8-alquilo, C1-C8-alquilamino, aminocarbonilo, C1-C8-alquilamino-carbonilo, di(C1-C8-alquil)amino, di(C1-C8-alquil)aminocarbonilo, di(C1-C8-alquil)aminocarbonil-metoxi, o o R2 o R3 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico que tiene de 5 a 10 átomos de anillo de los cuales 1, 2 o 3 son heteroátomos;R4 y R5 son cada uno independientemente hidrógeno o C1-C8-alquilo, o R4 es hidrógeno y R5 es hidroxi-C1-C8-alquilo, acilo, -SO2R8 o -CON(R6)R7, o R4 y R5 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros;R6 y R7 son cada uno independientemente hidrógeno o C1-C8-alquilo, o R6 y R7 junto con el átomo de nitrógeno al cual se unen denotan un grupo heterocíclico integrado por 5 o 6 miembros;R8 es C1-C8-alquilo, C1-C8-haloalquilo, o fenilo opcionalmente substituido por C1-C8-alquilo;X es -C(=O)-, -O-, -CH2-, o CH(OH);Y es oxígeno o azufre;m es 1, 2, 3 o 4; y n, p y q son cada uno 0 o 1, n+p+q=1 o 2, n+q=1, p+q=1, y cuando n es 0, p es 0.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0206218A GB0206218D0 (en) | 2002-03-15 | 2002-03-15 | Organic compounds |
GB0229627A GB0229627D0 (en) | 2002-12-19 | 2002-12-19 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5611125A2 true CO5611125A2 (es) | 2006-02-28 |
Family
ID=28043401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO04091228A CO5611125A2 (es) | 2002-03-15 | 2004-09-14 | Derivados de azetidina como antagonistas del receptor ccr-3 |
Country Status (18)
Country | Link |
---|---|
US (1) | US7288537B2 (es) |
EP (1) | EP1487435A1 (es) |
JP (2) | JP4332433B2 (es) |
KR (1) | KR100706270B1 (es) |
CN (1) | CN1638761A (es) |
AR (1) | AR041786A1 (es) |
AU (1) | AU2003227072B2 (es) |
BR (1) | BR0308419A (es) |
CA (1) | CA2479266A1 (es) |
CO (1) | CO5611125A2 (es) |
IL (1) | IL164016A0 (es) |
MX (1) | MXPA04009057A (es) |
NO (1) | NO20044373L (es) |
NZ (1) | NZ535082A (es) |
PL (1) | PL371055A1 (es) |
RU (1) | RU2314292C2 (es) |
TW (2) | TW200305395A (es) |
WO (1) | WO2003077907A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004228028B2 (en) | 2003-04-03 | 2009-12-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
WO2004113297A2 (en) * | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
CA2534550A1 (en) * | 2003-09-15 | 2005-03-24 | Novartis Ag | 1, 3-disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases |
GB0402101D0 (en) | 2004-01-30 | 2004-03-03 | Novartis Ag | Organic compounds |
US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
US7662910B2 (en) | 2004-10-20 | 2010-02-16 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
GB0607196D0 (en) * | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0720390D0 (en) * | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) * | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
SG11202007072RA (en) | 2018-01-26 | 2020-08-28 | Rapt Therapeutics Inc | Chemokine receptor modulators and uses thereof |
CN110498750B (zh) * | 2019-09-02 | 2021-10-15 | 南通大学 | 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法 |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2093456B (en) | 1980-10-08 | 1984-12-05 | Robins Co Inc A H | 1-r1-3-phenozyazetidines |
US5095014A (en) * | 1990-12-07 | 1992-03-10 | A. H. Robins Company, Incorporated | 3-(2-chloro-4-(trifluoromethyl)phenoxy)-1-azetidine carboxamides having anticonvulsant activity |
WO1999004794A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
GB0019006D0 (en) * | 2000-08-04 | 2000-09-20 | Astrazeneca Ab | Novel compounds |
GB0117387D0 (en) * | 2001-07-17 | 2001-09-05 | Novartis Ag | Organic compounds |
-
2003
- 2003-03-13 TW TW092105495A patent/TW200305395A/zh unknown
- 2003-03-13 AR ARP030100876A patent/AR041786A1/es not_active Application Discontinuation
- 2003-03-13 TW TW096115427A patent/TW200800167A/zh unknown
- 2003-03-14 KR KR1020047013800A patent/KR100706270B1/ko not_active IP Right Cessation
- 2003-03-14 MX MXPA04009057A patent/MXPA04009057A/es active IP Right Grant
- 2003-03-14 IL IL16401603A patent/IL164016A0/xx unknown
- 2003-03-14 RU RU2004130487/04A patent/RU2314292C2/ru not_active IP Right Cessation
- 2003-03-14 CA CA002479266A patent/CA2479266A1/en not_active Abandoned
- 2003-03-14 CN CNA038056488A patent/CN1638761A/zh active Pending
- 2003-03-14 PL PL03371055A patent/PL371055A1/xx not_active Application Discontinuation
- 2003-03-14 JP JP2003575960A patent/JP4332433B2/ja not_active Expired - Fee Related
- 2003-03-14 AU AU2003227072A patent/AU2003227072B2/en not_active Ceased
- 2003-03-14 EP EP03744367A patent/EP1487435A1/en not_active Withdrawn
- 2003-03-14 WO PCT/EP2003/002715 patent/WO2003077907A1/en active Application Filing
- 2003-03-14 US US10/507,139 patent/US7288537B2/en not_active Expired - Fee Related
- 2003-03-14 NZ NZ535082A patent/NZ535082A/en unknown
- 2003-03-14 BR BR0308419-1A patent/BR0308419A/pt not_active IP Right Cessation
-
2004
- 2004-09-14 CO CO04091228A patent/CO5611125A2/es not_active Application Discontinuation
- 2004-10-14 NO NO20044373A patent/NO20044373L/no not_active Application Discontinuation
-
2008
- 2008-11-27 JP JP2008302924A patent/JP2009102325A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1487435A1 (en) | 2004-12-22 |
BR0308419A (pt) | 2005-01-18 |
TW200800167A (en) | 2008-01-01 |
JP2009102325A (ja) | 2009-05-14 |
PL371055A1 (en) | 2005-06-13 |
NZ535082A (en) | 2006-08-31 |
CA2479266A1 (en) | 2003-09-25 |
RU2314292C2 (ru) | 2008-01-10 |
NO20044373L (no) | 2004-10-14 |
MXPA04009057A (es) | 2005-01-25 |
RU2004130487A (ru) | 2005-07-10 |
US7288537B2 (en) | 2007-10-30 |
IL164016A0 (en) | 2005-12-18 |
KR20040091690A (ko) | 2004-10-28 |
KR100706270B1 (ko) | 2007-04-11 |
AU2003227072A1 (en) | 2003-09-29 |
JP4332433B2 (ja) | 2009-09-16 |
TW200305395A (en) | 2003-11-01 |
AU2003227072B2 (en) | 2006-08-10 |
US20050222118A1 (en) | 2005-10-06 |
WO2003077907A1 (en) | 2003-09-25 |
AR041786A1 (es) | 2005-06-01 |
CN1638761A (zh) | 2005-07-13 |
JP2005526773A (ja) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5611125A2 (es) | Derivados de azetidina como antagonistas del receptor ccr-3 | |
ES2189502T3 (es) | Metodo para la prevencion de citalopram. | |
AR031597A1 (es) | Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3 | |
ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
ES2546851T3 (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
CO5080780A1 (es) | Derivado de amida y antagonista de nociceptina | |
PE20030809A1 (es) | Derivados de piperidina como antagonistas de la hormona concentradora de la melanina (mch) | |
CO5721002A2 (es) | Derivados de acido 3-(4-benciloxifenil) propanoico | |
PE20030808A1 (es) | Derivados triciclicos heterociclicos como antagonistas receptores de trombina | |
CO5601018A2 (es) | Derivados de n-fenil-2-pirimidin-amina | |
BRPI0506927A (pt) | compostos orgánicos | |
ECSP055883A (es) | Nuevos derivados de piridazin-3(2h)-ona | |
ECSP034611A (es) | Aminotiazoles y su uso como antagonistas del receptor de adenosina | |
AR028531A1 (es) | Compuestos organicos | |
ES2072779T3 (es) | Derivados aminoacidos anfoteros. | |
CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
DOP2011000281A (es) | Derivados de benzofurano | |
UY26048A1 (es) | Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica | |
CO5590924A2 (es) | Derivados de indolilalquilamina como ligandos de 5- hidroxitriptamina-6 | |
CO4650117A1 (es) | Derivados de bencilsulfuro y proceso para su produccion . | |
ES2179005T3 (es) | Compuesto de cromeno. | |
CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
CO5140116A1 (es) | Compuestos espiro derivados de imidazo-benzazepina con actividad antihistaminica y sus procesos de obtencion a partir de sus intermediarios de sintesis | |
AR006189A1 (es) | Aminoalquil-eteres y acilaminoalquil-eteres, procedimiento para su preparacion y su utilizacion como antagonistas de receptores de bradiquinina | |
CO5550437A2 (es) | Compuestos quimicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |